Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 364

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 364
---
,579,423 |   |     |      | 2,901,137 |   |
| Net loss per share of common shares, basic and diluted                                 |     | $                               |    (12.81 | ) |     | $    |    (12.20 | ) |

The Company’s potentially dilutive securities, which include convertible Preferred Stock, options to purchase common stock, and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:

|                                  |     | Nine Months Ended September 30, |            |     |      |            |
|                                  |     |                            2024 |            |     | 2023 |            |
| Convertible Preferred Stock      |     |                                 | 27,149,206 |     |      | 14,399,245 |
| Options to purchase common stock |     |                                 |  3,652,051 |     |      |  2,001,849 |
| Unvested restricted common stock |     |                                 |    119,639 |     |      |    317,745 |
| Total                            |     |                                 | 30,920,896 |     |      | 16,718,839 |

13. Subsequent Events The Company has evaluated subsequent events after September 30, 2024, through November 26, 2024, the date these financial statements were available to be issued, and February 3, 2025, for the reverse stock split described below. Stock Split The Company’s Board approved a 1-for-1.4611 reverse stock split of its issued and outstanding common stock, which also resulted in a proportional adjustment to the conversion price for each series of its convertible Preferred Stock, and to the exercise prices and number of shares of common stock underlying the outstanding stock options, which became effective on January 31, 2025. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. 2025 Equity Plans In January 2025